安图生物(603658) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,031,147,048.85, representing a year-on-year increase of 26.21%[4] - The net profit attributable to shareholders was CNY 240,200,411.27, reflecting a growth of 40.07% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 232,096,786.92, an increase of 37.36% year-on-year[4] - The basic and diluted earnings per share were both CNY 0.41, marking a rise of 41.38% from the previous year[5] - Total operating revenue for Q1 2022 reached ¥1,031,147,048.85, a 26.1% increase from ¥817,001,562.13 in Q1 2021[18] - Net profit for Q1 2022 was ¥246,970,997.71, representing a 41.0% increase compared to ¥175,062,601.81 in Q1 2021[19] - Total profit for Q1 2022 was ¥284,445,290.79, compared to ¥192,568,587.71 in Q1 2021, marking a 47.8% increase[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 9,628,036,184.62, up 4.28% from the end of the previous year[5] - The company's total assets amounted to approximately ¥9.63 billion, an increase from ¥9.23 billion as of December 31, 2021, representing a growth of about 4.4%[16] - The total liabilities of the company were approximately ¥2.05 billion, an increase from ¥1.83 billion, which is a rise of about 12.1%[16] - The company's equity attributable to shareholders was approximately ¥7.44 billion, up from ¥7.28 billion, showing an increase of about 2.3%[16] Cash Flow - The net cash flow from operating activities was CNY 181,963,679.96, which decreased by 29.85% year-on-year[4] - Cash flow from operating activities for Q1 2022 was ¥181,963,679.96, down 29.8% from ¥259,377,417.68 in Q1 2021[20] - Total cash and cash equivalents at the end of the period reached $911.7 million, up from $370.8 million in the previous period, indicating a significant increase of 145%[21] - The net increase in cash and cash equivalents for the period was $144.3 million, compared to an increase of $43.3 million in the previous period, representing a growth of over 233%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,030[9] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., held 55.25% of the shares[9] Expenses - Research and development expenses for Q1 2022 totaled ¥120,785,632.35, an increase of 16.4% from ¥103,758,719.19 in Q1 2021[18] - Sales expenses for Q1 2022 were ¥189,098,011.68, up 22.7% from ¥154,143,382.03 in Q1 2021[18] Other Financial Metrics - The weighted average return on equity increased by 0.64 percentage points to 3.25%[5] - The company's current assets reached approximately ¥5.84 billion, up from ¥5.56 billion in the previous year, indicating an increase of around 5.1%[14] - Cash and cash equivalents stood at approximately ¥913.66 million, compared to ¥769.40 million in the same period last year, reflecting a growth of about 18.7%[14] - The accounts receivable amounted to approximately ¥989.30 million, slightly up from ¥989.06 million, indicating a marginal increase of about 0.02%[14] - The inventory value increased to approximately ¥681.07 million from ¥589.34 million, representing a growth of about 15.6%[14] - The company reported a short-term loan of ¥100 million, consistent with the previous year's figure of ¥100.06 million[16] - The total non-current assets were approximately ¥3.79 billion, an increase from ¥3.67 billion, reflecting a growth of about 3.0%[15] - The company's other receivables increased to approximately ¥30.92 million from ¥28.80 million, indicating a growth of about 7.4%[14] Comprehensive Income - The company reported a decrease in comprehensive income for Q1 2022, totaling ¥246,929,536.64 compared to ¥175,181,369.97 in Q1 2021[19] Investment Activities - Cash flow from investment activities showed a net outflow of $238.7 million, compared to a net inflow of $23.4 million in the previous period[21] - The company reported a total investment cash outflow of $520 million, down from $609.2 million in the previous period, indicating a reduction of approximately 14.6%[21] Financing Activities - Cash inflow from financing activities totaled $390 million, a substantial increase compared to $2.1 million in the previous period[21] - Cash outflow for financing activities was $186.9 million, down from $241.8 million in the previous period, reflecting a decrease of approximately 22.7%[21] Accounting Standards - The company did not apply the new accounting standards for the current year, as indicated in the report[21] Report Release - The report was released by the board of directors on April 25, 2022, under the supervision of key financial personnel[21]